

Preventive medicine: Charité and Siemens Healthineers jointly develop innovative concepts

- **Cooperation agreement for joint research in preventive medicine**
- **Raise awareness about preventable diseases**
- **Reduce healthcare costs**

Charité – Universitätsmedizin Berlin and Siemens Healthineers will work more closely together in preventive medicine. As part of a cooperation agreement, they are developing innovative measures to prevent diseases and promote health. Combining their respective expertise, the partners will jointly strengthen the research and clinical implementation of patient-centered preventive care.

"Prevention is a central component of our Strategy 2030 'Rethinking Health'," said Charité Executive Board Chairman Professor Heyo K. Kroemer. "Charité's goal is to help identify health risks at an early stage and prevent diseases as far as possible to enable proactive and sustainable care. The existing partnership between Charité and Siemens Healthineers will now be expanded to include the area of prevention—a forward-looking step towards the joint research and development of innovative care concepts."

"We are pleased to further deepen our decades-long partnership with Charité and to expand it into the field of disease prevention. Together, we want to raise awareness of preventive medical care in Germany, improve access to the best possible care and prevent diseases wherever possible," said Siemens Healthineers Chief Executive Bernd Montag.

Initially, the partners aim to explore the potential of modern preventative care in the field of heart diseases as part of their collaboration. Cardiovascular diseases are the leading cause of death in Germany but



Siemens Healthineers AG
Siemensstraße 3
91301 Forchheim
Germany



Charité – Universitätsmedizin Berlin
Chariteplatz 1
10117 Berlin
Germany

according to studies, up to 80 percent of cases may be preventable. Currently, routine clinical examinations often only detect advanced pathological changes in the cardiovascular system. To address this, screening programs as well as risk scores and profiles will be developed to identify at-risk groups and to design precision therapies —with the goal of implementing them in clinical practice as quickly as possible. New imaging techniques, for example, can generate more detailed and precise images. In addition, advanced image processing and AI-based tools will be applied to these images in an automated way. This will allow early visualization of high-risk but still reversible vascular changes, enabling timely medical intervention.

Charité and Siemens Healthineers will now set up joint research projects aimed at enabling faster, more targeted treatment of patients, for example through new diagnostic and treatment protocols with the help of AI. In addition, AI-supported imaging techniques, patient group risk profiles, and personalized care approaches will be examined, further developed, and validated through scientific studies. Targeted prevention strategies and research are essential for better preventive care—efforts that can significantly improve public health, enhance quality of life, and reduce healthcare costs.

The research projects also include the development of a so-called "digital twin"— a digital replica that reflects relevant data and characteristics of the real person. This digital twin can be used to simulate individual health conditions and therapies, test preventive approaches and treatment options, or gain a better understanding of disease progression.

A press picture is available [here](#).

Media contact

Siemens Healthineers

Heiko Jahr

+49 162 2568150; heiko.jahr@siemens-healthineers.com

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

Charité – Universitätsmedizin Berlin

Markus Heggen

Pressesprecher

+49 30 450 570 400; presse@charite.de

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.

Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe. All of our clinical care, research and teaching is delivered by physicians and researchers of the highest international standard. Charité proudly lays claim to more than half of all German Nobel Prize winners in Physiology or Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich. Charité is internationally renowned for its excellence in teaching and training. The Charité is the joint medical faculty of Freie Universität Berlin and Humboldt-Universität zu Berlin. Charité extends over four campuses, and has over 100 different Departments and Institutes, which make up a total of 17 different CharitéCenters. Having marked its 300-year anniversary in 2010, Charité is now one of the largest employers in Berlin. www.charite.de/en